

16th February, 2026

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
--	--

Sub: USFDA inspection at the manufacturing facility of Enzene Biosciences Limited, a subsidiary of the Company in India located at Chakan, Pune

Dear Sir/Madam,

This is to inform you that the United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) on 13th February, 2026 at the manufacturing facility of Enzene Biosciences Limited (“Enzene”), a subsidiary of the Company in India located at Chakan, Pune.

At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations. Enzene has achieved Zero observations related to data integrity – a critical validation of Enzene’s quality systems and the reliability of regulatory filings.

Enzene is in the process of preparing and submitting its response to the USFDA within the stipulated timeline and has initiated appropriate corrective and preventive actions.

Kindly take the same on record.

Sincerely,

For Alkem Laboratories Limited

Manish Narang

President- Legal, Company Secretary and Compliance Officer